- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Waldenström macroglobulinaemia
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 583KB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 201KB)
Zanubrutinib – July 2024
Zanubrutinib; Capsule 80 mg; Brukinsa®
Last updated
30 May 2025